title: The effect of prostanoids on hepatic bile flow in dogs with normal liver and bile duct cell hyperplasia.
abstract: Bile flow rates and composition are subject to a wide variety of neural, endocrine and paracrine influences. The effects of these multiple factors may be different in the diseased liver compared to the response produced in the normal liver. As prostanoids may have a therapeutic role in liver disease it was intended to evaluate the effects of two principal therapeutic prostanoids, prostaglandin E2 and prostacyclin, on bile flow in dogs with a normal liver and in dogs with hepatotoxin-induced liver injury. Initially, in awake animals with chronic biliary and gastric fistulas the bile flow response to prostaglandin E2 and prostacyclin was evaluated and compared to the response produced by bile salt infusion alone and to that produced by the standard choleretic hormones, secretin and glucagon. The animals were then fed alpha-naphthylisothiocyanate (ANIT) and the studies repeated. ANIT is a hepatoxin that produces bile duct cell hyperplasia which was confirmed in dogs by demonstrating that ANIT increased [3H]thymidine incorporation by isolated canine bile duct cells. In normal dogs, the prostanoids, secretin, and glucagon increased hepatic bile flow. 10 days of ANIT feeding produced a hypercholeresis. While secretin was able to stimulate the hyperplastic biliary epithelium and increase bile flow over values produced by the hyperplastic biliary epithelium alone, neither prostaglandin E2, prostacyclin, or glucagon appeared to stimulate the hyperplastic biliary epithelium. As ANIT produced evidence of cholestasis and hepatocellular damage, only secretin would seem to have a potential therapeutic role in increasing bile flow in cholestatic liver disorders associated with bile duct cell hyperplasia.
authors.affiliation: Department of Surgery, St Louis University School of Medicine, MO 63110, USA.
authors.forename: H
authors.initials: H
authors.lastname: Solomon
authors.forename: J
authors.initials: J
authors.lastname: Contis
authors.forename: A P
authors.initials: AP
authors.lastname: Li
authors.forename: D L
authors.initials: DL
authors.lastname: Kaminski
mesh_terms: D015058:1-Naphthylisothiocyanate; D000818:Animals; D001646:Bile / Q000187:drug effects* / Q000378:metabolism; D001647:Bile Acids and Salts / Q000097:blood; D001649:Bile Duct Diseases / Q000139:chemically induced* / Q000378:metabolism; D002779:Cholestasis / Q000378:metabolism; D003135:Common Bile Duct / Q000473:pathology*; D015232:Dinoprostone / Q000494:pharmacology; D004285:Dogs; D011464:Epoprostenol / Q000494:pharmacology; D005934:Glucagon / Q000494:pharmacology; D006965:Hyperplasia; D012633:Secretin / Q000494:pharmacology
chemical_list: D001647:Bile Acids and Salts; D012633:Secretin; D015058:1-Naphthylisothiocyanate; D005934:Glucagon; D011464:Epoprostenol; D015232:Dinoprostone